NCT02466503View on ClinicalTrials.gov

Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers With Charcoal Block

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
AsthmaChronic Obstructive Pulmonary Disease (COPD)
Interventions
DRUG

Fluticasone propionate

Inhaled corticosteroid, pMDI

DRUG

Salmeterol (as xinafoate)

Beta-agonist, LABA, pMDI

Trial Locations (1)

Unknown

Clinical Pharmacology Unit of Mackay Memorial Hospital Tamshui Branch, New Taipei City

Sponsors
All Listed Sponsors
lead

Intech Biopharm Ltd.

INDUSTRY

NCT02466503 - Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers With Charcoal Block | Biotech Hunter | Biotech Hunter